Covalent Modifier Discovery Using Hydrogen/Deuterium Exchange-Mass Spectrometry.

Covalent ligands are generally filtered out of chemical libraries used for high-throughput screening, because electrophilic functional groups are considered to be pan-assay interference compounds (PAINS). Therefore, screening strategies that can distinguish true covalent ligands from PAINS are required. Hydrogen/deuterium-exchange mass spectrometry (HDX-MS) is a powerful tool for evaluating protein stability. Here, we report a covalent modifier screening approach using HDX-MS. In this study, HDX-MS was used to classify peroxisome proliferator-activated receptor γ (PPARγ) and vitamin D receptor ligands. HDX-MS could discriminate the strength of ligand-protein interactions. Our HDX-MS screening method identified LT175 and nTZDpa, which can bind concurrently to the PPARγ ligand-binding domain (PPARγ-LBD) with synergistic activation. Furthermore, iodoacetic acid was identified as a novel covalent modifier that stabilizes the PPARγ-LBD.

[1]  A. Dömling,et al.  Covalent inhibitors: a rational approach to drug discovery , 2020, RSC medicinal chemistry.

[2]  H. Kojima,et al.  Cyclization Reaction-Based Turn-on Probe for Covalent Labeling of Target Proteins. , 2020, Cell chemical biology.

[3]  J. Choi,et al.  Rational Design and Synthesis of Reversible Covalent PPARγ Antagonistic Ligands Inhibiting Ser273 Phosphorylation , 2019, Asian Journal of Organic Chemistry.

[4]  C. Carlberg,et al.  Vitamin D and Its Synthetic Analogs , 2019, Journal of medicinal chemistry.

[5]  T. Itoh,et al.  Identification of the Histidine Residue in Vitamin D Receptor That Covalently Binds to Electrophilic Ligands. , 2018, Journal of medicinal chemistry.

[6]  H. Kojima,et al.  On-site reaction for PPARγ modification using a specific bifunctional ligand. , 2017, Bioorganic & medicinal chemistry.

[7]  J. Olzmann,et al.  Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity. , 2017, ACS chemical biology.

[8]  Hye-Jin Yoon,et al.  Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site. , 2017, Biochimica et biophysica acta. Proteins and proteomics.

[9]  T. Mitsudomi,et al.  Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy , 2016, Cancer science.

[10]  T. Itoh,et al.  17-OxoDHA Is a PPARα/γ Dual Covalent Modifier and Agonist. , 2016, ACS chemical biology.

[11]  T. Itoh,et al.  Helix12-Stabilization Antagonist of Vitamin D Receptor. , 2016, Bioconjugate chemistry.

[12]  A. Olson,et al.  Proteome-wide covalent ligand discovery in native biological systems , 2016, Nature.

[13]  R. A. Bauer.  Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. , 2015, Drug discovery today.

[14]  Patrick R Griffin,et al.  HDX-MS guided drug discovery: small molecules and biopharmaceuticals. , 2014, Current opinion in structural biology.

[15]  C. Klein,et al.  Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.

[16]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[17]  Randy J. Read,et al.  phenix.mr_rosetta: molecular replacement and model rebuilding with Phenix and Rosetta , 2012, Journal of Structural and Functional Genomics.

[18]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[19]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[20]  Lars Konermann,et al.  Hydrogen exchange mass spectrometry for studying protein structure and dynamics. , 2011, Chemical Society reviews.

[21]  K. Morikawa,et al.  The nuclear receptor PPARγ individually responds to serotonin‐ and fatty acid‐metabolites , 2010, The EMBO journal.

[22]  David Baker,et al.  Quantitative reactivity profiling predicts functional cysteines in proteomes , 2010, Nature.

[23]  Y. Inaba,et al.  Potent antagonist for the vitamin D receptor: vitamin D analogues with simple side chain structure. , 2010, Journal of medicinal chemistry.

[24]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[25]  Andrew L Hopkins,et al.  Fragment screening by surface plasmon resonance. , 2010, ACS medicinal chemistry letters.

[26]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[27]  E. Novellino,et al.  Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. , 2008, Journal of medicinal chemistry.

[28]  Yoshitomo Hamuro,et al.  Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA , 2008, Nature.

[29]  J. Schwabe,et al.  Structural basis for the activation of PPARγ by oxidized fatty acids , 2008, Nature Structural &Molecular Biology.

[30]  F. G. Njoroge,et al.  Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. , 2008, Accounts of chemical research.

[31]  Scott A. Busby,et al.  Partial agonists activate PPARgamma using a helix 12 independent mechanism. , 2007, Structure.

[32]  N. Greenfield.  Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions , 2006, Nature Protocols.

[33]  A. Barnett,et al.  DPP‐4 inhibitors and their potential role in the management of type 2 diabetes , 2006, International journal of clinical practice.

[34]  S. Tuske,et al.  Hydrogen/deuterium‐exchange (H/D‐Ex) of PPARγ LBD in the presence of various modulators , 2006, Protein science : a publication of the Protein Society.

[35]  Scott A. Busby,et al.  Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. , 2006, Analytical chemistry.

[36]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[37]  Bruce A. Johnson,et al.  Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.

[38]  T. Willson,et al.  Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. , 2002, Biochemistry.

[39]  R. Stroud,et al.  Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[41]  J. Lehmann,et al.  A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. , 1999, Diabetes.

[42]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[43]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[44]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[45]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[46]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.